Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until December 31, 2011. Switch to any other Anti vascular endothelial growth factor (anti VEGF) treatment will be documented. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.
Study Type
OBSERVATIONAL
Enrollment
137
Patients with wet AMD treated with ranibizumab as prescribed by physician
Unnamed facility
Many Locations, Portugal
Changes in visual acuity after start of Anti vascular endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard
Time frame: Baseline and 24 months
Demographic characteristics of patients included in the study (Age, Sex, Race)
Time frame: Baseline
Mean time from first clinical presentation to diagnosis
Time frame: Baseline
Mean time from diagnosis to treatment
Time frame: Time from diagnosis to treatment: Up to 24 months
Mean time from diagnosis to end of follow-up
Time frame: Time from diagnosis to end of follow-up: up to 48 months
Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chart
Time frame: Baseline and 24 months
Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT)
Time frame: Baseline and 24 months
Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA)
Time frame: Baseline and 24 months
Average number of treatments given from diagnosis to end of follow-up
Time frame: After 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.